NCT04972110 2025-10-30
ATTACC
Repare Therapeutics
Phase 1/2 Terminated
Clinical Trials
11 trialsNCT06682780 2025-09-25
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT06953323 2025-08-13
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT05455424 2025-05-15
NERO
University Hospital Southampton NHS Foundation Trust
Phase 2 Completed
NCT06365970 2025-02-03
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
University of Pittsburgh
Phase 2 Withdrawn
NCT04185831 2024-08-22
MEGALiT
Uppsala University Hospital
Phase 2 Active not recruiting
NCT03209401 2024-02-05
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Georgetown University
Phase 1 Terminated
NCT04235101 2024-01-05
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
Byondis B.V.
Phase 1 Completed
NCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT03497429 2021-11-09
A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed